Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Trial Results with OROS® Hydromorphone

Published byMyron Miller Modified over 6 years ago

Similar presentations

Presentation on theme: "Clinical Trial Results with OROS® Hydromorphone"— Presentation transcript:

1 Clinical Trial Results with OROS® Hydromorphone
Mark S. Wallace, MD, John Thipphawong, MD  Journal of Pain and Symptom Management  Volume 33, Issue 2, Pages S25-S32 (February 2007) DOI: /j.jpainsymman Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

2 Fig. 1 Interference of chronic pain with daily activities before and after oral administration of OROS® hydromorphone once daily for at least 7 days.6 Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

3 Fig. 2 Interference of chronic cancer pain with daily activities after OROS® hydromorphone once daily or controlled-release morphine twice daily for ≥12 days.3 BPI scored from 0 (no interference) to 10 (complete interference). Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

4 Fig. 3 Breakthrough medication use in patients with chronic cancer pain.3 Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

5 Fig. 4 Global evaluation of therapy among patients with chronic cancer pain treated with once-daily OROS® hydromorphone or twice-daily controlled-release morphine.3 Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

6 Fig. 5 Improvements in overall pain relief among patients with chronic low back pain treated with OROS® hydromorphone.11 Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

7 Fig. 6 BPI pain severity in patients with low back pain treated with OROS® hydromorphone in a 7-week, open-label study.11 BPI scored from 0 (no interference) to 10 (complete interference). Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

8 Fig. 7 Effect of OROS® hydromorphone on quality of life in patients with moderate to severe low back pain.11 Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

9 Fig. 8 Mean changes from baseline pain relief and pain intensity associated with OROS® hydromorphone and extended-release oxycodone in patients with chronic osteoarthritis pain. Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

10 Fig. 9 Mean changes from baseline in MOS sleep Indices I and II after treatment with OROS® hydromorphone or extended-release oxycodone in patients with chronic osteoarthritis pain. Sleep problems Index I is derived from items 4 (get enough sleep to feel rested upon waking in the morning), 5 (awaken short of breath or with a headache), 7 (have trouble falling asleep), 8 (awaken during your sleep time and have trouble falling asleep again), 9 (have trouble staying awake during the day), and 12 (get the amount of sleep you needed) of the MOS sleep assessment; higher scores indicate greater sleep problems. Sleep problems Index II is derived from items 1 (time to fall asleep), 3 (feel that sleep was not quiet), 4, 5, 6 (feel drowsy or sleepy during the day), 7, 8, 9, and 12 of the MOS sleep assessment; higher scores indicate greater sleep problems. Journal of Pain and Symptom Management  , S25-S32DOI: ( /j.jpainsymman ) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Download ppt "Clinical Trial Results with OROS® Hydromorphone"

Similar presentations

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.
Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,
Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation  Samuel Vokurka, MD, PhD 

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation  Samuel Vokurka, MD, PhD 
One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia
Chronic Pain Management in Older Adults: Special Considerations

Chronic Pain Management in Older Adults: Special Considerations
Managing Metastatic Bone Pain: The Role of Bisphosphonates

Managing Metastatic Bone Pain: The Role of Bisphosphonates
Switching Breast Cancer Patients with Progressive Bone Metastases to Third- Generation Bisphosphonates: Measuring Impact Using the Functional Assessment.

Switching Breast Cancer Patients with Progressive Bone Metastases to Third- Generation Bisphosphonates: Measuring Impact Using the Functional Assessment.
Neurotoxicity from Chronic Opioid Therapy After Successful Palliative Treatment for Painful Bone Metastases  Andrew Broadbent, BMedSc, MBChB, FRACP, FAChPM,

Neurotoxicity from Chronic Opioid Therapy After Successful Palliative Treatment for Painful Bone Metastases  Andrew Broadbent, BMedSc, MBChB, FRACP, FAChPM,
Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K
Managing Metastatic Bone Pain: The Role of Bisphosphonates

Managing Metastatic Bone Pain: The Role of Bisphosphonates
Wen Jing Chung, MD, MS, Gregory H. Pharo, DO 

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO 
Chronic Pain Management in Older Adults: Special Considerations

Chronic Pain Management in Older Adults: Special Considerations
A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations  Mary E. Lynch,

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations  Mary E. Lynch,
Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief  Giovambattista Zeppetella, FRCP  Journal.

Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief  Giovambattista Zeppetella, FRCP  Journal.
Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety  Meredith Noble, MS, Stephen J. Tregear,

Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety  Meredith Noble, MS, Stephen J. Tregear,
Patterns of Pain and Interference in Patients with Painful Bone Metastases: A Brief Pain Inventory Validation Study  Jackson S.Y. Wu, MD, MSc, FRCPC,

Patterns of Pain and Interference in Patients with Painful Bone Metastases: A Brief Pain Inventory Validation Study  Jackson S.Y. Wu, MD, MSc, FRCPC,
Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain  Jacques R. Caldwell, MD, Ronald J. Rapoport,

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain  Jacques R. Caldwell, MD, Ronald J. Rapoport,
Reliability, Validity, and Responsiveness of the Daily Sleep Interference Scale Among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients 

Reliability, Validity, and Responsiveness of the Daily Sleep Interference Scale Among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients 
David M. Simpson, MD, Lydia Estanislao, MD, Stephen J

David M. Simpson, MD, Lydia Estanislao, MD, Stephen J
Establishing Mild, Moderate, and Severe Scores for Cancer-Related Symptoms: How Consistent and Clinically Meaningful Are Interference-Based Severity Cut-Points? 

Establishing Mild, Moderate, and Severe Scores for Cancer-Related Symptoms: How Consistent and Clinically Meaningful Are Interference-Based Severity Cut-Points? 

Similar presentations

Ads by Google